Elaine W. Chong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Elaine W. Chong has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Zhengyang Liu
Department of Surgery, The Royal Melbourne Hospital, Parkville, VIC, Australia
3 shared publications - Dev Raveendran
Department of Surgery, The Royal Melbourne Hospital, Parkville, VIC, Australia
1 shared publication - Elsie Chan
Royal Victorian Eye and Ear Hospital East Melbourne Victoria Australia
1 shared publication - Sachin Phakey
The Royal Melbourne Hospital
1 shared publication - Spiros Fourlanos
Department of Diabetes and Endocrinology The Royal Melbourne Hospital Melbourne Victoria Australia
1 shared publication - Sujan A. Surendran
Centre for Eye Research Australia Melbourne Victoria Australia
1 shared publication
Latest Publications
- 7 September 2026
- Published by Wiley in Clinical & Experimental Ophthalmology
- Vol. 54 (8) , 1078-1079
Femtosecond Laser‐Created Corneal Allogenic Intrastromal Ring Segments for Keratoconus: Technical Promise and the Challenge of Donor Tissue Stewardship
- 7 September 2026
- Published by Wiley in Clinical & Experimental Ophthalmology
- Vol. 54 (8) , 1078-1079
Femtosecond Laser‐Created Corneal Allogenic Intrastromal Ring Segments for Keratoconus: Technical Promise and the Challenge of Donor Tissue Stewardship
- 21 August 2026
- Published by BMJ in British Journal of Ophthalmology
Aflibercept 8 mg versus faricimab for macular oedema due to retinal vein occlusion: a systematic review and network meta-analysis
Aim: To indirectly evaluate the comparative efficacy and safety of aflibercept 8 mg and faricimab in treating retinal vein occlusion (RVO)-associated macular oedema. Methods: We searched MEDLINE, Embase and Cochrane CENTRAL from inception to 11 December 2025. We performed frequentist network meta-analysis on efficacy and safety outcomes at loading phase completion (24–40 weeks), with 4 weekly aflibercept 2 mg as the common comparator. Results: Three trials with 2174 adults were included. 8 weekly aflibercept 8 mg with five 4 weekly loading doses was more likely to achieve a best corrected visual acuity (BCVA) of ≥69 letters (Snellen 20/40, unconditional driving threshold) compared with 4 weekly faricimab (risk ratio (RR) 1.18, 95% CI 1.03 to 1.35). 4 weekly faricimab demonstrated greater rates of complete resolution of intraretinal and subretinal fluid against 8 weekly aflibercept 8 mg with both five and three 4 weekly loading doses (both RR 1.12, 95% CI 1.01 to 1.25). There was no evidence of a difference in mean BCVA improvement between agents. Both aflibercept 8 mg and 2 mg regimens were associated with a greater risk of clinically significant intraocular pressure (IOP) rise of 30–60 min post-injection compared with 4 weekly faricimab (8 weekly aflibercept 8 mg with five 4 weekly loading doses, RR 6.42, 95% CI 1.85 to 22.34; 8 weekly aflibercept 8 mg with three 4 weekly loading doses, RR 6.97, 95% CI 2.02 to 24.08; 4 weekly aflibercept 2 mg, RR 2.12, 95% CI 1.01 to 4.47). Conclusion: Aflibercept 8 mg and faricimab show comparable overall visual efficacy for RVO-associated macular oedema. Indirect comparisons suggest aflibercept 8 mg may increase the probability of achieving driving vision, while faricimab may offer greater anatomical drying and a lower risk of acute IOP elevation. PROSPERO registration number: CRD420251249785.
- 21 August 2026
- Published by BMJ in British Journal of Ophthalmology
Aflibercept 8 mg versus faricimab for macular oedema due to retinal vein occlusion: a systematic review and network meta-analysis
Aim: To indirectly evaluate the comparative efficacy and safety of aflibercept 8 mg and faricimab in treating retinal vein occlusion (RVO)-associated macular oedema. Methods: We searched MEDLINE, Embase and Cochrane CENTRAL from inception to 11 December 2025. We performed frequentist network meta-analysis on efficacy and safety outcomes at loading phase completion (24–40 weeks), with 4 weekly aflibercept 2 mg as the common comparator. Results: Three trials with 2174 adults were included. 8 weekly aflibercept 8 mg with five 4 weekly loading doses was more likely to achieve a best corrected visual acuity (BCVA) of ≥69 letters (Snellen 20/40, unconditional driving threshold) compared with 4 weekly faricimab (risk ratio (RR) 1.18, 95% CI 1.03 to 1.35). 4 weekly faricimab demonstrated greater rates of complete resolution of intraretinal and subretinal fluid against 8 weekly aflibercept 8 mg with both five and three 4 weekly loading doses (both RR 1.12, 95% CI 1.01 to 1.25). There was no evidence of a difference in mean BCVA improvement between agents. Both aflibercept 8 mg and 2 mg regimens were associated with a greater risk of clinically significant intraocular pressure (IOP) rise of 30–60 min post-injection compared with 4 weekly faricimab (8 weekly aflibercept 8 mg with five 4 weekly loading doses, RR 6.42, 95% CI 1.85 to 22.34; 8 weekly aflibercept 8 mg with three 4 weekly loading doses, RR 6.97, 95% CI 2.02 to 24.08; 4 weekly aflibercept 2 mg, RR 2.12, 95% CI 1.01 to 4.47). Conclusion: Aflibercept 8 mg and faricimab show comparable overall visual efficacy for RVO-associated macular oedema. Indirect comparisons suggest aflibercept 8 mg may increase the probability of achieving driving vision, while faricimab may offer greater anatomical drying and a lower risk of acute IOP elevation. PROSPERO registration number: CRD420251249785.
- 29 December 2025
- Published by Elsevier in Ophthalmology
- Vol. 133 (5) , 589-598
Rate and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy with Semaglutide Use for Diabetes and Weight Loss
- 29 December 2025
- Published by Elsevier in Ophthalmology
- Vol. 133 (5) , 589-598
Rate and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy with Semaglutide Use for Diabetes and Weight Loss
- 13 December 2024
- Published by Taylor & Francis in Ophthalmic Epidemiology
- Vol. 32 (5) , 533-542
Corneal Transplantation in Australia Over 29 Years: A Retrospective Analysis of Medicare Data from 1994 to 2022
We aim to report the frequency and distribution of corneal transplantation, by age, sex, and state/territory, in Australia over a > 25-year period from 1994 to 2022, including during COVID-19 lockdowns. Using data from Medicare, Australia's Government-funded health insurance scheme, we retrospectively analysed corneal transplants performed from January 1994 to December 2022. From 1994 to 2022, there were 27,536 corneal transplantation services processed by Medicare. Transplants tended to be more common in males in younger age groups (67.7% male in 15-24-year-olds), and in females in older age groups (59.2% female in 75-84-year-olds). Most transplants were performed in New South Wales (9,438 services, 34.3%), Queensland (7,722, 28.0%), and Victoria (5,209, 18.9%). Annual corneal transplantation rates in Australia tended to decrease from 1994 to 2006 (lowest rate during study period), falling by 31%, and then increased by 81%, from 2006 to 2022 (end of study period). Annual repeat corneal transplantation rates (i.e. second and subsequent transplants) increased from 2004 to 2022, rising 301%. During Australia's nationwide 2020 COVID-19 lockdown (from March to April), monthly transplantation rates decreased by 31%. We performed a longitudinal analysis of corneal transplantation in Australia using a comprehensive, routinely collected, population-based data source. Prior studies examining corneal transplantation have interrogated data from the Australian Corneal Graft Registry, which relies on voluntary reporting. Corneal transplantation rates have increased during the last 15 years, likely as new corneal transplant techniques have evolved, with increasing demand for corneal donation and eye banking services.
- 13 December 2024
- Published by Taylor & Francis in Ophthalmic Epidemiology
- Vol. 32 (5) , 533-542
Corneal Transplantation in Australia Over 29 Years: A Retrospective Analysis of Medicare Data from 1994 to 2022
We aim to report the frequency and distribution of corneal transplantation, by age, sex, and state/territory, in Australia over a > 25-year period from 1994 to 2022, including during COVID-19 lockdowns. Using data from Medicare, Australia's Government-funded health insurance scheme, we retrospectively analysed corneal transplants performed from January 1994 to December 2022. From 1994 to 2022, there were 27,536 corneal transplantation services processed by Medicare. Transplants tended to be more common in males in younger age groups (67.7% male in 15-24-year-olds), and in females in older age groups (59.2% female in 75-84-year-olds). Most transplants were performed in New South Wales (9,438 services, 34.3%), Queensland (7,722, 28.0%), and Victoria (5,209, 18.9%). Annual corneal transplantation rates in Australia tended to decrease from 1994 to 2006 (lowest rate during study period), falling by 31%, and then increased by 81%, from 2006 to 2022 (end of study period). Annual repeat corneal transplantation rates (i.e. second and subsequent transplants) increased from 2004 to 2022, rising 301%. During Australia's nationwide 2020 COVID-19 lockdown (from March to April), monthly transplantation rates decreased by 31%. We performed a longitudinal analysis of corneal transplantation in Australia using a comprehensive, routinely collected, population-based data source. Prior studies examining corneal transplantation have interrogated data from the Australian Corneal Graft Registry, which relies on voluntary reporting. Corneal transplantation rates have increased during the last 15 years, likely as new corneal transplant techniques have evolved, with increasing demand for corneal donation and eye banking services.
- 27 February 2022
- Published by Wiley in Clinical & Experimental Ophthalmology
- Vol. 50 (3) , 267-269
‘Aye, there's the rub’—Ocular allergy and keratoconus
- 27 February 2022
- Published by Wiley in Clinical & Experimental Ophthalmology
- Vol. 50 (3) , 267-269
‘Aye, there's the rub’—Ocular allergy and keratoconus
- 1 May 2015
- Published by Wiley in Clinical & Experimental Ophthalmology
- Vol. 43 (4) , 297-299
Fenofibrate and diabetic retinopathy
- 1 May 2015
- Published by Wiley in Clinical & Experimental Ophthalmology
- Vol. 43 (4) , 297-299
Fenofibrate and diabetic retinopathy